Savara Inc SVRA
$5.46
▼ -1.44%
($-0.08)
🔥 High Short Interest
🗓️ Earnings Next Week
Open
$5.54
Prev Close
$5.54
Day Range
$5.35 – $5.63
52W Range
$2.43 – $7.01
Market Cap
$1.12B
Beta
0.25
EPS (TTM)
$-0.56
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2001-06-25 |
| Shares Out. | 204,930,000 |
| Website | savarapharma.com/ ↗ |
| Phone | 15126141848 |
| Employees | 70 |
| Net Income | -$37.3M |
| Free Cash Flow | -$107.0M |
| Total Assets | $221.6M |
| Total Liabilities | $45.6M |
| Equity | $176.0M |
About Savara Inc
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Savara Inc is a publicly traded company under the ticker symbol SVRA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-07-01)